{"url_path":"/sec/apvo/8-k/2026-06-30/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-290473-index.html","accession_number":"0001193125-26-290473","cik":"0001671584","ticker":"APVO","issuer_name":"Aptevo Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-290473-index.html","primary_entity_key":"0001671584","primary_entity_name":"Aptevo Therapeutics Inc."},"word_count":270,"has_tables":true,"body_markdown":"Item 1.01. Entry into a Material Definitive Agreement.\n\nOn June 29, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into a Grant Award Agreement (the “Agreement”) with the Andy Hill Cancer Research Endowment (CARE) Fund (the “Grantor”), a Washington State–established public research endowment.\n\nUnder the Agreement, the Grantor will provide the Company with $1,499,951.00 in funding on a reimbursement basis only to support Investigational New Drug (“IND”) - enabling studies for APVO451, the Company’s trispecific antibody candidate for solid tumor indications during the grant period. Funding is subject to the Company providing any applicable matching non-state contributions in an amount at least equal to the CARE Fund’s contribution.\n\nThe project period is expected to extend through June 2028, subject to earlier termination in accordance with the Agreement.\n\nPayments will be made based on reimbursement of eligible costs incurred by the Company in accordance with an approved budget and are subject to the achievement of specified milestones, reporting requirements, and compliance with applicable terms and conditions. The Agreement includes customary provisions regarding use of funds, audit rights, reporting obligations, and termination, including termination for cause or failure to achieve project requirements.\n\nThe Company retains ownership of intellectual property generated under the project, subject to certain obligations, including acknowledgment of Grantor support and commitments related to commercialization and public benefit.\n\nThe foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026."}